This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreDigital therapeutics (DTx) is a category of digital health, which is defined as products that delive...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreInnovative therapies for rare diseases may only be available in a select number of countries in Euro...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...
Read moreWith many anticipated new medicines for rare diseases, countries are beginning to prepare appropriat...
Read moreThe HST process is a method for evaluating medicines and treatments specifically indicated for ultra...
Read moreNICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...
Read more